Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Castle Biosciences Q2 Adj. EPS $0.15 Beats $(0.49) Estimate, Sales $86.19M Beat $71.53M Estimate

Author: Benzinga Newsdesk | August 04, 2025 04:07pm
Castle Biosciences (NASDAQ:CSTL) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $(0.49) by 130.8 percent. This is a 51.61 percent decrease over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $86.19 million which beat the analyst consensus estimate of $71.53 million by 20.50 percent. This is a 0.94 percent decrease over sales of $87.00 million the same period last year.

Posted In: CSTL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist